Literature DB >> 25202067

Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.

Si Hyoung Kim1, Hae-Young Shin2, Yong-Sun Kim3, Jun Goo Kang1, Chul Sik Kim1, Sung-Hee Ihm1, Moon Gi Choi1, Hyung Joon Yoo1, Seong Jin Lee4.   

Abstract

BACKGROUND/AIM: The aim of the present study was to elucidate whether tunicamycin (TM) induces paraptosis as a cell death subroutine in anaplastic thyroid carcinoma (ATC) cells.
MATERIALS AND METHODS: 8505C, CAL62 and FRO cells were used. After treatment of TM, cell survival and morphology were investigated. The effect of the BRAF(V600E) inhibitor PLX4032 in combination with TM was evaluated.
RESULTS: In FRO cells, TM induced paraptosis characteristic of cytoplasmic vacuolation and endoplasmic reticulum (ER) swelling, which was not associated with caspase activation and ER stress. TM-induced paraptosis was ameliorated by pre-treatment with the translation inhibitor cycloheximide, while it was accelerated by pre-treatment with the proteasome inhibitor MG132. PLX4032 augmented TM-induced paraptosis.
CONCLUSION: TM induces paraptosis relevant to de novo protein synthesis and proteasomal activity, and inhibition of BRAF(V600E) potentiates TM-induced paraptosis in FRO cells harboring BRAF(V600E). Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Anaplastic thyroid carcinoma; BRAF; paraptosis; tunicamycin

Mesh:

Substances:

Year:  2014        PMID: 25202067

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Paraptosis triggers mitochondrial pathway-mediated apoptosis in Alzheimer's disease.

Authors:  Dong-Pei Jia; Song Wang; Bao-Chao Zhang; Fang Fang
Journal:  Exp Ther Med       Date:  2015-05-29       Impact factor: 2.447

2.  Tunicamycin inhibits progression of glioma cells through downregulation of the MEG-3-regulated wnt/β-catenin signaling pathway.

Authors:  Xin Li; Lei Xue; Qin Peng
Journal:  Oncol Lett       Date:  2018-04-03       Impact factor: 2.967

3.  MEG-3-mediated Wnt/β-catenin signaling pathway controls the inhibition of tunicamycin-mediated viability in glioblastoma.

Authors:  Xiangyu Cui; Dezhou Sun; Bin Shen; Xin Wang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

4.  Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.

Authors:  Yoon Ju Choi; Jae-Eon Lee; Hyun Dong Ji; Bo-Ra Lee; Sang Bong Lee; Kil Soo Kim; In-Kyu Lee; Jungwook Chin; Sung Jin Cho; Jaetae Lee; Sang-Woo Lee; Jeoung-Hee Ha; Yong Hyun Jeon
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

5.  Tunicamycin suppresses breast cancer cell growth and metastasis via regulation of the protein kinase B/nuclear factor-κB signaling pathway.

Authors:  Xiaoli Wang; Wei Xiong; Yiyin Tang
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

6.  Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways.

Authors:  Chan Ho Park; Se Eun Han; Il Seong Nam-Goong; Young Il Kim; Eun Sook Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.